Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial to evaluate the safety and preliminary efficacy of SYS6020 CAR T-cells in patients with refractory generalized myasthenia gravis is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• SYS6020 CAR T-cells

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Myasthenia Gravis | Phase 1 | Status: RECRUITING